Heidi Peynado de Pena
Endocrinology, Diabetes & Metabolism · Great Falls, MTNPI 1265883607
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,916 of the $4,535 with a category attached, or 64.3%. 23 manufacturers reported payments, led by Medtronic at 54.7% of the total. 2025 is the largest year on record at $2,164, 2.0 times the $1,061 reported in 2020.
Across 120 payments — averaging $37.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Corcept Therapeutics$734
- AstraZeneca$199
- Novartis$185
- Boehringer Ingelheim$163
- Amgen$101
- plus $670 from 17 others
What the payments were for
- Travel & lodging$1,61836%
- Food & beverage$2,91664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $2,481 |
| Corcept Therapeutics | 31 | $734 |
| AstraZeneca | 7 | $199 |
| Novartis | 9 | $185 |
| Boehringer Ingelheim | 9 | $163 |
| Amgen | 6 | $101 |
| Lilly USA, LLC | 6 | $101 |
| Xeris Pharmaceuticals, Inc. | 5 | $99 |
| Astellas Pharma US Inc | 2 | $52 |
| Ascendis Pharma Endocrinology Inc | 2 | $51 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Exact Sciences | 3 | $49 |
| Merck | 3 | $46 |
| Insulet Corporation | 2 | $41 |
| Averitas Pharma Inc. | 2 | $35 |
| Tandem Diabetes Care, Inc. | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $18 |
| AbbVie | 1 | $16 |
| Bayer | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$703
- MINIMED 780G$561
How this compares
Too few endocrinology, diabetes & metabolism providers in Montanato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 11 | $449,505 |
| MounjaroTirzepatide | 64 | $74,707 |
| TrulicityDulaglutide | 54 | $73,987 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 54 | $47,816 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $42,565 |
| OzempicSemaglutide | 33 | $41,013 |
| JardianceEmpagliflozin | 38 | $38,328 |
| Cinacalcet Hcl | 12 | $23,355 |
| FarxigaDapagliflozin Propanediol | 23 | $20,483 |
| Novolog FlexpenInsulin Aspart | 76 | $16,234 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 120 | $14,074 |
| BaqsimiGlucagon | 22 | $13,290 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $12,960 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $8,205 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $8,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kyowa Kirin, Inc.Crysvita | $18 | $449,50511 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Insulin Lispro | $101 | $162,628151 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $163 | $43,20254 claims |
| AstraZenecaFarxiga | $199 | $20,48323 claims |
| Sanofi-aventis U.S. LLCLantus | $22 | $4,78319 claims |
| AbbVieSynthroid | $16 | $1,87721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Montanaon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Great Falls
- Barry CohanGreat Falls$11K
- Michael SalimGreat Falls$846
- Lauren KleessBillings$1K
- Bhanu PaturiBozeman$996
- Christopher CorsiMissoula$978
- Michele DanicichMissoula$799
- Meredith RossMissoula$582
- David JohnsonBillings$479
- Jose DesouzaKalispell$454
- Brian RoseBozeman$401
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.